Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_96339

China has treated 86 people with CRISPR genome editing

29 January 2018
Appeared in BioNews 935

China has administered CRISPR genome editing to at least 86 cancer patients, a new report has revealed.

The Wall Street Journal has found evidence of 11 genome editing clinical trials in China, geared towards targeting an array of cancers and HIV infection. One is reported to have started as early as 2015.

US researchers were the first to use CRISPR to edit DNA. However, genome-editing trials have yet to be approved in the country. China, by contrast, has much less intensive regulation in this area.

'China shouldn't have been the first one to do [a human genome editing trial],' Dr Shixiu Wu, who is leading one of China's first such trials at Hangzhou Cancer Hospital, told the Wall Street Journal. 'But there are fewer restrictions.'

Researchers from University of Pennsylvania in the USA are yet to receive final regulatory clearance for CRISPR-based cancer therapeutics. Dr Wu's trial is using genome editing to treat oesophageal cancer. The team aims to edit the genome of immune T cells extracted from patient blood to halt the production of PD-1, a protein which helps cancer cells evade the immune system, before reinfusing the modified cells into the patients.

The report also highlighted instances of less stringent, sometimes inconsistent review processes for human trials faced by Chinese researchers compared with their Western counterparts. The latter must field hospital review boards, ethics committees and government agencies before receiving approval.

Dr Carl June, lead scientist from the University of Pennsylvania study, spoke of regulatory asymmetry between the USA and China. 'We are at a dangerous point in losing our lead in biomedicine. It is hard to know what the ideal is between moving quickly and making sure patients are safe.'

Despite its purported efficacy and ease of use in laboratory-based studies, CRISPR research faces concerns regarding unintended alterations within DNA ('off-target' effects, see BioNews 903), or even rejection by the patient's immune system (see BioNews 933).

Calling CRISPR a double-edged sword, Dr Wu said: 'If we don't try, we will never know.'

SOURCES & REFERENCES
China Has Already Gene-Edited 86 People With CRISPR
Gizmodo |  22 January 2018
China modifies genes of 86 people using CRISPR gene editing technology
Useful Reporter |  24 January 2018
China, Unhampered by Rules, Races Ahead in Gene-Editing Trials
Wall Street Journal |  21 January 2018
Chinese scientists used Crispr gene editing on 86 human patients
Quartz |  23 January 2018
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
16 April 2018 - by Shaoni Bhattacharya 
Europe's first clinical trial to use genome editing in humans has received approval to start later this year...
2 October 2017 - by Dr Rachel Brown 
A genome editing technique called 'base editing' has been used to correct the mutation causing the inherited blood disorder beta-thalassemia in human embryos...
4 September 2017 - by Annabel Slater 
A group of scientists have challenged the landmark study which reported the first successful editing of human embryos for a genetic disease...
25 July 2016 - by Rachel Siden 
Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans – on patients with lung cancer – this August...
26 October 2015 - by Isobel Steer 
Scientists in China have used the gene-editing technique CRISPR/Cas9 to create dogs with increased muscle mass...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.